Previous close | 0.0100 |
Open | 0.0100 |
Bid | 0.0000 |
Ask | 0.0500 |
Strike | 52.50 |
Expiry date | 2024-07-19 |
Day's range | 0.0100 - 0.0100 |
Contract range | N/A |
Volume | |
Open interest | 138 |
In the closing of the recent trading day, Bristol Myers Squibb (BMY) stood at $42.19, denoting a -0.09% change from the preceding trading day.
Bristol Myers (BMY) wins FDA approval for Krazati, in combination with Erbitux, as a targeted treatment option for adult patients with KRASG12C-mutated locally advanced or metastatic colorectal cancer.
PRINCETON, N.J., June 21, 2024--Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI® (adagrasib) in Combination with Cetuximab for Adult Patients with...